Cargando…

Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity?

BACKGROUND: Various musculoskeletal and autoimmune manifestations have been described in patients with coronavirus disease 2019 (COVID-19). OBJECTIVES: This study aims to investigate the prevalence and etiology of arthritis in post-COVID Egyptian patients. METHODS: We included 100 post-COVID Egyptia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taha, Sara Ibrahim, Samaan, Sara Farid, Ibrahim, Rehab Ali, El-Sehsah, Eman Mousa, Youssef, Mariam Karam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Libbey Eurotext 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831681/ https://www.ncbi.nlm.nih.gov/pubmed/35118946 http://dx.doi.org/10.1684/ecn.2021.0471

Ejemplares similares

Can Complete Blood Count Picture Tell Us More About the Activity of Rheumatological Diseases?
por: Taha, Sara I, et al.
Publicado: (2022)

Post COVID-19 syndrome in a prospective cohort study of Egyptian patients
por: Gamal, Dalia Mohamed, et al.
Publicado: (2022)

Neutrophil Extracellular Traps Contribute to COVID-19 Hyperinflammation and Humoral Autoimmunity
por: Torres-Ruiz, Jiram, et al.
Publicado: (2021)

Immunopathology of Hyperinflammation in COVID-19
por: Gustine, Joshua N., et al.
Publicado: (2021)

Management of hyperinflammation in COVID-19 patients
por: Suberviola, Borja, et al.
Publicado: (2022)

COVID-19 Hyperinflammation: What about Neutrophils?
por: Didangelos, Athanasios
Publicado: (2020)

Frontal encephalopathy related to hyperinflammation in COVID-19
por: Cani, Ilaria, et al.
Publicado: (2020)

Delving beneath the surface of hyperinflammation in COVID-19
por: Reddy, Kiran, et al.
Publicado: (2020)

Hyperinflammation with COVID-19: The key to patient deterioration?()()
por: Haigh, Kathryn, et al.
Publicado: (2020)

Hyperinflammation, T cells, and endotoxemia
por: Inoue, Makoto, et al.
Publicado: (2015)

Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome
por: Afrin, Lawrence B., et al.
Publicado: (2020)

Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
por: Tanner, Tamara, et al.
Publicado: (2020)

IgGs drive COVID-19 myeloid hyperinflammation
por: Park, Matthew D.
Publicado: (2020)

Attenuating hyperinflammation in COVID-19: A change in paradigm?
por: Molnar, Zsolt, et al.
Publicado: (2020)

ACEi reduces hypertension-induced hyperinflammation in COVID-19
por: Lim, Gregory B.
Publicado: (2021)

COVID‐19: lambda interferon against viral load and hyperinflammation
por: Andreakos, Evangelos, et al.
Publicado: (2020)

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
por: Ritchie, Andrew I, et al.
Publicado: (2020)

Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in COVID-19
por: Sohrabi, Yahya, et al.
Publicado: (2021)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
por: Maynard, Suzanne, et al.
Publicado: (2021)

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
por: Papadopoulou, Charalampia, et al.
Publicado: (2020)

A brewing storm: The neuropsychological sequelae of hyperinflammation due to COVID-19
por: Cothran, Thomas P., et al.
Publicado: (2020)

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
por: TUFAN, Abdurrahman, et al.
Publicado: (2020)

COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps
por: Borges, Leandro, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
por: Bonaventura, Aldo, et al.
Publicado: (2022)

Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19
por: Smeets, Tim J. L., et al.
Publicado: (2022)

Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation
por: Marwah, Vikas, et al.
Publicado: (2021)

Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors
por: Gasparyan, Armen Yuri, et al.
Publicado: (2022)

Kawasaki-Erkrankung oder Hyperinflammations-Syndrom?
Publicado: (2020)

Kawasaki-Erkrankung oder Hyperinflammations-Syndrom?
por: -, -
Publicado: (2020)

Personal protective equipment (PPE) use and its relation to accidents among construction workers
por: Sehsah, Radwa, et al.
Publicado: (2020)

Endothelial Protein kinase D1 is a major regulator of post-traumatic hyperinflammation
por: Schönfelder, Jonathan, et al.
Publicado: (2023)

Post VV-ECMO Weaning Hyperinflammation—Can Prophylactic Hemoadsorption Treatment Prevent Complications?
por: Kovacevic, Pedja, et al.
Publicado: (2023)

Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series
por: Clark, Kristina E N, et al.
Publicado: (2020)

Network Pharmacology Reveals That Resveratrol Can Alleviate COVID-19-Related Hyperinflammation
por: Xiao, Zijian, et al.
Publicado: (2021)

A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling
por: Hasan, Djo, et al.
Publicado: (2021)

Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation
por: TUFAN, Abdurrahman, et al.
Publicado: (2021)

Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19
por: Zaid, Younes, et al.
Publicado: (2021)

Metabolic modeling of single bronchoalveolar macrophages reveals regulators of hyperinflammation in COVID-19
por: Zhao, Qiuchen, et al.
Publicado: (2022)

Blood Hyperviscosity: A Novel Link Between Hyperinflammation and Hypercoagulability in COVID-19
por: Bonaventura, Aldo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eb85rdq6csojp4ku5ao0opklrl